Literature DB >> 22609249

Aldosterone, oxidative stress, and NF-κB activation in hypertension-related cardiovascular and renal diseases.

Nina Queisser1, Nicole Schupp.   

Abstract

The mineralocorticoid aldosterone regulates electrolyte and fluid balance and is involved in blood pressure homoeostasis. Classically, it binds to its intracellular mineralocorticoid receptor to induce expression of proteins influencing the reabsorption of sodium and water in the distal nephron. Aldosterone gained special attention when large clinical studies showed that blocking its receptor in patients with cardiovascular diseases reduced their mortality. These patients present increased plasma aldosterone levels. The exact mechanisms of the potential toxic effects of aldosterone leading to cardiovascular damage are not known yet. The observation of reduced nitric oxide bioavailability in hyperaldosteronism implied the generation of oxidative stress by aldosterone. Subsequent studies confirmed the increase of oxidative stress markers in patients with chronic heart failure and in animal models of hyperaldosteronism. The effects of reactive oxygen species have been related to the activation of transcription factors, such as NF-κB. This review summarizes the present-day knowledge of aldosterone-induced oxidative stress and NF-κB activation in humans and different experimental models.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609249     DOI: 10.1016/j.freeradbiomed.2012.05.011

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  23 in total

Review 1.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

Review 2.  The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease.

Authors:  M Elizabeth Moss; Brigett Carvajal; Iris Z Jaffe
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

Review 3.  The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction.

Authors:  Fei Wu; Yun Lin; Qingyong Liu
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

4.  Neuroendocrine profile in a rat model of psychosocial stress: relation to oxidative stress.

Authors:  Marilena Colaianna; Stefania Schiavone; Margherita Zotti; Paolo Tucci; Maria Grazia Morgese; Liselotte Bäckdahl; Rikard Holmdahl; Karl-Heinz Krause; Vincenzo Cuomo; Luigia Trabace
Journal:  Antioxid Redox Signal       Date:  2013-04-20       Impact factor: 8.401

Review 5.  Stress physiology in marine mammals: how well do they fit the terrestrial model?

Authors:  Shannon Atkinson; Daniel Crocker; Dorian Houser; Kendall Mashburn
Journal:  J Comp Physiol B       Date:  2015-04-26       Impact factor: 2.200

Review 6.  Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis.

Authors:  Elise P Gomez-Sanchez
Journal:  Steroids       Date:  2014-12       Impact factor: 2.668

7.  NFKB1-mediated downregulation of microRNA-106a promotes oxidative stress injury and insulin resistance in mice with gestational hypertension.

Authors:  Yunxia Guo; Zhaofang Liu; Ming Wang
Journal:  Cytotechnology       Date:  2021-01-04       Impact factor: 2.058

Review 8.  Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2.

Authors:  Peter Stenvinkel; Glenn M Chertow; Prasad Devarajan; Adeera Levin; Sharon P Andreoli; Sripal Bangalore; Bradley A Warady
Journal:  Kidney Int Rep       Date:  2021-05-04

Review 9.  Preclinical studies of low back pain.

Authors:  Judith A Strong; Wenrui Xie; Feguens J Bataille; Jun-Ming Zhang
Journal:  Mol Pain       Date:  2013-03-28       Impact factor: 3.395

10.  Long-term inhibition of UCHL1 decreases hypertension and retinopathy in spontaneously hypertensive rats.

Authors:  Shasha Liu; Chengfang Wang; Jianmin Lu; Guangzheng Dai; Huixin Che; Wei He
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.